Covid19 Clinical Trial
— POCAH-COVIDOfficial title:
Prevalence Of COVID-19 Among Health-workers in a French General Hospital
NCT number | NCT04548908 |
Other study ID # | POCAH-COVID19 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 3, 2020 |
Est. completion date | June 30, 2021 |
The aim of this study is to evaluate the prevalence of COVID-19 among the workers of our hospital and the factors that are likely to influence this prevalence. It must be underlined that our hospital is settled in two towns and both hospital sites had different missions regarding the admissions of COVID-19-infected patients.
Status | Recruiting |
Enrollment | 1300 |
Est. completion date | June 30, 2021 |
Est. primary completion date | April 30, 2021 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - hospital staff working at the Centre Hospitalier Sud Essonne, - employed by the Centre Hospitalier Sud Essonne between March, 5th, 2020, and August, 31rst, 2020, - with the result of an RT PCR test or a serologic test, - this (these) result(s) must have been/be communicated to the occupational health service of the hospital. Exclusion criteria: - interim workers, - workers in holidays during the entire period of inclusion above, - opposition to participate in this study. |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier Sud Essonne | Etampes |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Sud Essonne |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | General prevalence of COVID-19 | measures the prevalence of COVID-19 among the healthcare workers of the Centre Hospitalier Sud Essonne, defined as the hospital employees with positive serologic or RT-PCR tests. It must be underlined that the notion of "health workers" include the entire hospital staff ie doctors, nurses, administrative employees,... |
Through study completion, an average of 9 months | |
Secondary | Number of asymptomatic healthcare workers | no RT PCR or negative RT PCR and positive serologic test, positive RT PCR and no symptoms, |
Through study completion, an average of 9 months | |
Secondary | Number of symptomatic healthcare workers | Positive RT-PCR test or serologic test with symptoms. | Through study completion, an average of 9 months | |
Secondary | Number of healthcare workers with a severe form of COVID-19 which led to an hospitalization | Positive serologic or RTC-PCR test and hospitalization | Through study completion, an average of 9 months | |
Secondary | Number of healthcare workers infected with COVID-19 and hospitalized in a critical care unit | Positive serologic or RTC-PCR test and hospitalization in a critical care unit | Through study completion, an average of 9 months | |
Secondary | Influencing factors of the prevalence of the COVID-19 among healthcare workers | age, gender, job, duration of employment in the hospital, hospital site of affectation, unit of affectation. |
Through study completion, an average of 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |